Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02774486
Other study ID # INQ/025115
Secondary ID
Status Completed
Phase N/A
First received March 22, 2016
Last updated January 1, 2018
Start date May 1, 2016
Est. completion date July 20, 2016

Study information

Verified date January 2018
Source InQpharm Group
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The primary cause of being overweight is an imbalance in calories consumed and energy expenditure. A surplus in energy intake might result in body fat deposition and thereby body weight gain. Therefore, food intake regulation is crucial to control the body weight gain.

Appetite regulation plays an important role in determining the food intake, which is a complex process influenced by the individual (physiology and psychology) and environment. Satiation (process that leads to the termination of eating) and satiety (decline in hunger, increase in fullness after a meal has finished) are the precursors of appetite regulation, which may be induced by various food components such as macronutrients, water, alcohol and non-digestible polysaccharides. High viscosity and swellable/bulking food components such as dietary fibre are expected to elicit stronger satiation/satiety than the macronutrients or clear liquid. Due to its unique physicochemical properties, dietary fibre has been recognized as potential ingredient that helps to enhance the sensation of satiety in the upper gut by increasing gastric distension and delaying gastric emptying, which subsequently reduces the food intake.

IQP-AK-102 comprises of a proprietary blend of dietary fibres known to promote a feeling a fullness. The objectives of this study are to evaluate the efficacy and safety of IQP-AK-102 on appetite reduction in overweight subjects during a 4-weeks interval.


Recruitment information / eligibility

Status Completed
Enrollment 36
Est. completion date July 20, 2016
Est. primary completion date July 20, 2016
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

1. Males and females, aged 18-65 years

2. BMI =25 and BMI <30 kg/m2

3. Generally in good health

4. Regular daily consumption of 3 main meals (breakfast, lunch, dinner)

5. Consistent regular physical activity (=4 hours of strenuous sportive activity per week) AND willingness to maintain the same level of sport activity throughout the study

6. Commitment to avoid the use of other weight loss and/or management products / programmes during the study

7. Commitment to complete the subject diary correctly and to adhere to the lifestyle recommended for this study

8. Stable concomitant medications (if any)

9. Stable body weight for the last 3 months prior to V1 (less than 5% self-reported change)

10. Subject's agreement to comply with study procedures

11. Negative pregnancy testing (beta HCG-test in urine) at V1 in females of childbearing potential

12. Women of child-bearing potential: willingness to use reliable method of contraception during the study period

Exclusion Criteria:

1. Known sensitivity to the components of the investigational product

2. Bariatric surgery in the last 12 months prior to V1

3. Abdominal surgery within the last 6 months prior to V1

4. Presence of any active gastrointestinal disease incl. stenosis in the gastrointestinal tract

5. Malabsorption disorders

6. Pancreatitis

7. History of eating disorders like bulimia, anorexia nervosa, binge-eating (within the last 12 months prior to V1)

8. Lack of appetite for any (unknown) reason

9. Use of medications that could influence gastrointestinal functions such as antibiotics, laxatives, opioids, anticholinergics, anti-diarrheals 3 months prior to V1 and during the study

10. Use of medications that could influence body weight (e.g. antidepressants) in the last 3 months prior to V1 and during the study

11. Any medication or use of products for the treatment of obesity (e.g. fat binder, fat burner, satiety products etc.) or treatment that could influence food absorption, in last 3 months before V1 and during the study

12. Gluten allergy

13. History of abuse of drugs, alcohol or medication

14. Exceeding moderate alcohol consumption (=21 units /week; 1 unit is equal 1/2 l of beer, or 200 ml of wine, or 50 ml hard liquor)

15. Smoking cessation within 6 months prior to V1 or during the study (regular smoking at the same level as prior to the study during the study is not an exclusion criteria)

16. Inability to comply with study procedures (e.g. due to language difficulties etc.)

17. Participation in similar studies or weight loss programs within the last 6 months prior to V1 and during the study

18. Participation in other clinical studies within the last 30 days prior to V1 and during the study

19. Clinically relevant deviations of laboratory values

20. Any other reason deemed suitable for exclusion, per investigator's judgement

Study Design


Related Conditions & MeSH terms


Intervention

Device:
IQP-AK-102
IQP-AK-102 has been qualified as a medical device (CE certificate has been ob- tained), class IIb, according to MDD 93/42/EEC, annex IX, rule 5.

Locations

Country Name City State
Germany Barbara Grube Berlin

Sponsors (1)

Lead Sponsor Collaborator
InQpharm Group

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Changes in appetite before and after breakfast 3 days a week (including one weekend day) using Haber Score (hunger, satiety) - Comparison between week 2 and week 3 (first week of the IP intake) as well as comparison between week 2 and week 6 (last week of the IP intake) 6 weeks
Primary Changes in appetite before and after breakfast 3 days a week (including one weekend day) using VAS (hunger, satiety, fullness, prospective food consumption). - Comparison between week 2 and week 3 (first week of the IP intake) as well as comparison between week 2 and week 6 (last week of the IP intake) 6 weeks
Secondary Changes in food intake using the subject diary Measured on the same days as appetite assessment (for breakfast, lunch, dinner, in between meal/snacks), during the run-in phase (three days a week, both weeks) and treatment phase (at first week of the IP intake (week 3),and during the last week of the IP intake, just before the V3, also three days a week). 6 weeks
Secondary Changes in body weight using calibrated weighing scales (Tanita BC-420 SMA) Body weight (kg) is measured in subjects wearing underwear and no shoes 6 weeks
Secondary Changes in BMI BMI is calculated as body weight (kg)/(height [m])2 6 weeks
Secondary Changes in waist circumference Waist circumference (cm) is measured at the level midway between the lateral lower rib margin and the iliac crest 6 weeks
Secondary Changes in hip circumference Hip circumference (cm) is measured as the maximal circumference over the buttocks 6 weeks
Secondary Changes in body fat content using validated electronic weighing scales according to the Body composition analyser BC-420MA (a bio-impedance analysis (BIA)) Measured as % and kg 6 weeks
Secondary Changes in fat-free mass using validated electronic weighing scales according to the Body composition analyser BC-420MA (a bio-impedance analysis (BIA)) Measured as % and kg 6 weeks
Secondary Global evaluation of efficacy by subjects The subjects will evaluate independently the efficacy of the IP (globally scaled evaluation with "very good", "good", "moderate" and "poor"). 6 weeks
Secondary Global evaluation of efficacy by investigator The investigators will evaluate independently the efficacy of the IP (globally scaled evaluation with "very good", "good", "moderate" and "poor"). 6 weeks
Secondary Blood pressure Measured using standard devices after an at least 5-minute rest 6 weeks
Secondary Pulse rate Measured using standard devices after an at least 5-minute rest 6 weeks
Secondary Global evaluation of safety by subjects The subjects will evaluate independently the tolerability of the IP (global scaled evaluation with "very good", "good", "moderate" and "poor"). 6 weeks
Secondary Global evaluation of safety by investigator The investigators will evaluate independently the tolerability of the IP (global scaled evaluation with "very good", "good", "moderate" and "poor"). 6 weeks
See also
  Status Clinical Trial Phase
Completed NCT04219189 - The Acute Effect of Vaping on Food Intake N/A
Active, not recruiting NCT02207049 - The Effect of Snack Consumption on Energy Intake in Preschoolers N/A
Recruiting NCT05417659 - Glycogen and Appetite N/A
Active, not recruiting NCT04148560 - Free-living Validation of the RFPM in Adolescents N/A
Completed NCT02484313 - The Effect of Snacks on Glycaemic Regulation in Children N/A
Completed NCT05507801 - Protein and Satiety in Older Adults (PROSAT) N/A
Completed NCT04862208 - Breakfast Consumption and Energy Balance in Active Adult Males N/A
Not yet recruiting NCT02119208 - Effects of the Intensity and the Timing of the Physical Activity in a Primary School N/A
Recruiting NCT06432517 - Sources and Mechanisms of Energy Compensation N/A
Not yet recruiting NCT06398340 - Identifying Wearable Biomarkers to Monitor Dietary Intake N/A
Completed NCT04655547 - Impact on Energy Intake by Implementing Recommended Food Texture Through Dietary Guidance N/A
Completed NCT02053025 - Appetite Regulation and Mycoprotein N/A
Completed NCT03143868 - Role of Acute Exercise Modality on Appetite Regulation and Energy Intake N/A
Completed NCT04788069 - Effect of Sourdough Breads Consumption on Postprandial Responses, Satiety and Food Intake at Subsequent Meal N/A
Withdrawn NCT05042349 - Pregnant Elite Athletes and Pregnant Women Exercising With Moderate Intensity
Active, not recruiting NCT05671965 - Effects of Oral Xylitol on Subsequent Energy Intake N/A
Completed NCT06015867 - Effect of Sourdough Bread Consumption on Postprandial Responses, Appetite Regulation and Energy Intake N/A
Recruiting NCT06230900 - Mass Balance of Orally Administered [14C] (3S,4S,5R)-1,3,4,5,6-pentahydroxy-hexan-2-one N/A
Completed NCT04713137 - Effects of Oral Pre-loads on Subsequent Energy Intake N/A
Completed NCT03072251 - Participation of Breast Milk Feeding Mothers in Research